About us

TARGTEX

TargTex is developing localized therapies for hard-to-treat tumors

TargTex has implemented a novel approach to identify promising targets that are overexpressed in cancers of significant unmet need. Our lead product engages a highly selective and unexplored target in Glioblastoma. This has been formulated as a perioperative hydrogel, delivering the drug directly to the site of action.

On a long-term perspective, TargTex aims to develop clinical candidates for different oncological indications. The GBM pilot project is the first step to become a sustainable company that will enable the development of other anticancer candidates.

Management team

João Seixas, PhD

Chief Executive Officer

Pedro Cal, PhD

Chief Operating Officer

Gonçalo Bernardes, DPhil

Scientific Director

Cláudia Faria, MD, PhD

Medical Director

Board of directors

João Seixas, PhD

Gonçalo Bernardes, DPhil

Miguel Botto

Joaquim Chaves

Advisory Board

Adília Hormigo

Neuro-oncologist, GBM expert

John Ford

Business and Financial expert